IGFBP3 and asthma: Even beyond the scope of diseases typically considered to be autoimmune, potential therapeutic responses might be anticipated through the targeting of the IGF-I pathway and IGFBP3, a report by Lee et al. opined on the plausible treatment of asthma with these and related approaches [107], given the pathway’s putative role in mediating airway hyper- responsiveness, fibrosis and inflammation.